메뉴 건너뛰기
Therapeutic Advances in Urology
Volumn 5, Issue 6, 2013, Pages 338-353
Recent developments in the treatment of renal cell carcinoma
Author keywords

immunotherapy; molecular subtypes; Renal cell carcinoma; targeted therapy
Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; EVEROLIMUS; INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN INHIBITOR;
EID: 84887686930     PISSN: 17562872     EISSN: 17562880     Source Type: Journal    
DOI: 10.1177/1756287213505672     Document Type: Review
Times cited : (67)
References (117)
  • 1
    • 79959609860 scopus 로고    scopus 로고
    • Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers
    • Adjei A. Schwartz B. Garmey E. (2011) Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers. The Oncologist 16: 788–799.
    • (2011) The Oncologist , vol.16 , pp. 788-799
    • Adjei, A.1    Schwartz, B.2    Garmey, E.3
  • 2
    • 33845413247 scopus 로고    scopus 로고
    • Birt–Hogg–Dube syndrome: clinicopathologic findings and genetic alterations
    • Adley B. Smith N. Nayar R. Yang X. (2006) Birt–Hogg–Dube syndrome: clinicopathologic findings and genetic alterations. Arch Pathol Lab Med 130: 1865–1870.
    • (2006) Arch Pathol Lab Med , vol.130 , pp. 1865-1870
    • Adley, B.1    Smith, N.2    Nayar, R.3    Yang, X.4
  • 3
    • 84880944039 scopus 로고    scopus 로고
    • Prolonged survival with personalized immunotherapy (AGS-003) in combination with sunitinib in unfavorable risk metastatic RCC
    • (Suppl. 6): abstract 357
    • Amin A. Dudek A. Logan T. Lance R. Holzbeierlien J. Master V. (2013) Prolonged survival with personalized immunotherapy (AGS-003) in combination with sunitinib in unfavorable risk metastatic RCC. J Clin Oncol 31(Suppl. 6): abstract 357.
    • (2013) J Clin Oncol , vol.31
    • Amin, A.1    Dudek, A.2    Logan, T.3    Lance, R.4    Holzbeierlien, J.5    Master, V.6
  • 4
    • 0037501437 scopus 로고    scopus 로고
    • Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay
    • Argani P. Lal P. Hutchinson B. Lui M. Reuter V. Ladanyi M. (2003) Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol 27: 750–761.
    • (2003) Am J Surg Pathol , vol.27 , pp. 750-761
    • Argani, P.1    Lal, P.2    Hutchinson, B.3    Lui, M.4    Reuter, V.5    Ladanyi, M.6
  • 5
    • 0034964421 scopus 로고    scopus 로고
    • Gene mutation in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma
    • Astuti D. Latif F. Dallol A. Dahlia P. Douglas F. George E. (2001) Gene mutation in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 69: 49–54.
    • (2001) Am J Hum Genet , vol.69 , pp. 49-54
    • Astuti, D.1    Latif, F.2    Dallol, A.3    Dahlia, P.4    Douglas, F.5    George, E.6
  • 6
    • 1542398693 scopus 로고    scopus 로고
    • Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma
    • Atkins M. Hidalgo M. Stadler W. Logan T. Dutcher J. Hudes G. (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22: 909–918.
    • (2004) J Clin Oncol , vol.22 , pp. 909-918
    • Atkins, M.1    Hidalgo, M.2    Stadler, W.3    Logan, T.4    Dutcher, J.5    Hudes, G.6
  • 7
    • 79957802759 scopus 로고    scopus 로고
    • Final results of the European advanced renal cell carcinoma sofrafenib (EU-ARCCS) expanded access study: a large open-label study in diverse community settings
    • Beck J. Procopio G. Bajetta E. Keilholz U. Negrier S. Szczylik C. (2011) Final results of the European advanced renal cell carcinoma sofrafenib (EU-ARCCS) expanded access study: a large open-label study in diverse community settings. Ann Oncol 22: 1812–1823.
    • (2011) Ann Oncol , vol.22 , pp. 1812-1823
    • Beck, J.1    Procopio, G.2    Bajetta, E.3    Keilholz, U.4    Negrier, S.5    Szczylik, C.6
  • 8
    • 0842325739 scopus 로고    scopus 로고
    • PD-L1/B7H1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) in transgenic CD8+ T cells
    • Blank C. Brown I. Peterson A. Spiotto M. Iwai Y. Honjo T. (2004) PD-L1/B7H1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) in transgenic CD8+ T cells. Cancer Res 64: 1140–1145.
    • (2004) Cancer Res , vol.64 , pp. 1140-1145
    • Blank, C.1    Brown, I.2    Peterson, A.3    Spiotto, M.4    Iwai, Y.5    Honjo, T.6
  • 9
    • 84862903106 scopus 로고    scopus 로고
    • Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
    • Brahmer J. Tykodi S. Chow L. Hwu W. Topalian S. Hwu P. (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455–2465.
    • (2012) N Engl J Med , vol.366 , pp. 2455-2465
    • Brahmer, J.1    Tykodi, S.2    Chow, L.3    Hwu, W.4    Topalian, S.5    Hwu, P.6
  • 10
    • 35648938219 scopus 로고    scopus 로고
    • Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer
    • Bukowski R. Kabbinavar F. Figlin R. Flaherty K. Srinivas S. Vaishampayan U. (2007) Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 25: 4536–4541.
    • (2007) J Clin Oncol , vol.25 , pp. 4536-4541
    • Bukowski, R.1    Kabbinavar, F.2    Figlin, R.3    Flaherty, K.4    Srinivas, S.5    Vaishampayan, U.6
  • 11
    • 0037407573 scopus 로고    scopus 로고
    • Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma
    • Cheville J. Lohse C. Zincke H. Weaver A. Blute M. (2003) Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 27: 612–624.
    • (2003) Am J Surg Pathol , vol.27 , pp. 612-624
    • Cheville, J.1    Lohse, C.2    Zincke, H.3    Weaver, A.4    Blute, M.5
  • 12
    • 1842529797 scopus 로고    scopus 로고
    • Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome
    • Cheville J. Lohse C. Zincke H. Weaver A. Leibovich B. (2004) Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol 28: 435–441.
    • (2004) Am J Surg Pathol , vol.28 , pp. 435-441
    • Cheville, J.1    Lohse, C.2    Zincke, H.3    Weaver, A.4    Leibovich, B.5
  • 13
    • 84867827863 scopus 로고    scopus 로고
    • Efficacy of cabozantinib (XL184) in patients with metastatic refractory renal cell carcinoma
    • (Suppl.): abstract 4504
    • Choueiri T. Pal S. McDermott D. Ramies D. Morrissey S. Lee Y. (2012) Efficacy of cabozantinib (XL184) in patients with metastatic refractory renal cell carcinoma. J Clin Oncol 30(Suppl.): abstract 4504.
    • (2012) J Clin Oncol , vol.30
    • Choueiri, T.1    Pal, S.2    McDermott, D.3    Ramies, D.4    Morrissey, S.5    Lee, Y.6
  • 14
    • 0041411517 scopus 로고    scopus 로고
    • Adjuvant high dose bolus interleukin-2 for patients with high risk renal cell carcinoma - A Cytokine Working Group Randomized Trial
    • Clark J. Atkins M. Urba W. Creech S. Figlin R. Dutcher J. (2003) Adjuvant high dose bolus interleukin-2 for patients with high risk renal cell carcinoma - A Cytokine Working Group Randomized Trial. J Clin Oncol 21: 3133–3140.
    • (2003) J Clin Oncol , vol.21 , pp. 3133-3140
    • Clark, J.1    Atkins, M.2    Urba, W.3    Creech, S.4    Figlin, R.5    Dutcher, J.6
  • 15
    • 84930479671 scopus 로고    scopus 로고
    • The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses
    • Coventry B. Ashdown M. (2012) The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses. Cancer Manage Res 4: 215–221.
    • (2012) Cancer Manage Res , vol.4 , pp. 215-221
    • Coventry, B.1    Ashdown, M.2
  • 16
    • 79960357893 scopus 로고    scopus 로고
    • A phase II study of bevacizumab and high dose aldesleukin (IL2) in patients with metastatic renal cell carcinoma
    • (15 Suppl.): abstract 4530
    • Dandamudi U. Ghebremichael M. Sosman J. Regan M. Atkins M. Clark J. (2010) A phase II study of bevacizumab and high dose aldesleukin (IL2) in patients with metastatic renal cell carcinoma. J Clin Oncol 28(15 Suppl.): abstract 4530.
    • (2010) J Clin Oncol , vol.28
    • Dandamudi, U.1    Ghebremichael, M.2    Sosman, J.3    Regan, M.4    Atkins, M.5    Clark, J.6
  • 17
    • 0028833027 scopus 로고
    • Renal medullary carcinoma. The seventh sickle cell nephropathy
    • Davis C. Jr Mostofi F. Sesterhenn I. (1995) Renal medullary carcinoma. The seventh sickle cell nephropathy. Am J Surg Pathol 19: 1–11.
    • (1995) Am J Surg Pathol , vol.19 , pp. 1-11
    • Davis, C.1    Mostofi, F.2    Sesterhenn, I.3
  • 18
    • 0034949144 scopus 로고    scopus 로고
    • Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases
    • Delahunt B. Eble J. McCredie M. Bethwaite P. Stewart J. Bilous A. (2001) Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum Pathol 32: 590–595.
    • (2001) Hum Pathol , vol.32 , pp. 590-595
    • Delahunt, B.1    Eble, J.2    McCredie, M.3    Bethwaite, P.4    Stewart, J.5    Bilous, A.6
  • 19
    • 67651056360 scopus 로고    scopus 로고
    • Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies
    • Dutcher J. DeSouza P. McDermott D. Figlin R. Berkenblit A. Thiele A. (2009) Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 26: 202–209.
    • (2009) Med Oncol , vol.26 , pp. 202-209
    • Dutcher, J.1    DeSouza, P.2    McDermott, D.3    Figlin, R.4    Berkenblit, A.5    Thiele, A.6
  • 20
    • 84655165029 scopus 로고    scopus 로고
    • Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy
    • Dutcher J. Nanus D. (2011) Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy. Med Oncol 28: 1530–1533.
    • (2011) Med Oncol , vol.28 , pp. 1530-1533
    • Dutcher, J.1    Nanus, D.2
  • 22
    • 84887775082 scopus 로고    scopus 로고
    • A description of the surgical experience in children, adolescents, and young adults with renal cell carcinoma: a report from the Children–s Oncology Group Study AREN 03B2
    • (Suppl. 2):, abstract 39
    • Ehrlich P. Cost N. Khanna G. Mullen E. Gratias E. Naranjo A. (2012) A description of the surgical experience in children, adolescents, and young adults with renal cell carcinoma: a report from the Children–s Oncology Group Study AREN 03B2. Br J Urol Int 110(Suppl. 2): 18, abstract 39.
    • (2012) Br J Urol Int , vol.110 , pp. 18
    • Ehrlich, P.1    Cost, N.2    Khanna, G.3    Mullen, E.4    Gratias, E.5    Naranjo, A.6
  • 23
    • 84885599759 scopus 로고    scopus 로고
    • Phase II efficacy and safety study of nintedanib versus sunitinib in previously untreated renal cell carcinoma patients
    • (Suppl.): abstract 4506
    • Eisen T. Shparyk Y. Jones R. MacLeod J. Temple G. Finnigan H. (2013) Phase II efficacy and safety study of nintedanib versus sunitinib in previously untreated renal cell carcinoma patients. J Clin Oncol 31(Suppl.): abstract 4506.
    • (2013) J Clin Oncol , vol.31
    • Eisen, T.1    Shparyk, Y.2    Jones, R.3    MacLeod, J.4    Temple, G.5    Finnigan, H.6
  • 24
    • 80051537004 scopus 로고    scopus 로고
    • Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer
    • Elfiky A. Aziz S. Conrad P. Siddiqui S. Hackl W. Maira M. (2011) Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer. J Transl Med 9: 133–143.
    • (2011) J Transl Med , vol.9 , pp. 133-143
    • Elfiky, A.1    Aziz, S.2    Conrad, P.3    Siddiqui, S.4    Hackl, W.5    Maira, M.6
  • 26
    • 37349080670 scopus 로고    scopus 로고
    • Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
    • Escudier B. Pluzanska A. Koralewski P. Ravaud A. Bracarda S. Szczylik C. (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: 2103–2111.
    • (2007) Lancet , vol.370 , pp. 2103-2111
    • Escudier, B.1    Pluzanska, A.2    Koralewski, P.3    Ravaud, A.4    Bracarda, S.5    Szczylik, C.6
  • 27
    • 63049093371 scopus 로고    scopus 로고
    • Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma
    • Feldman D. Baum M. Ginsberg M. Hassoun H. Flombaum C. Velasco S. (2009) Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 1432–1439.
    • (2009) J Clin Oncol , vol.27 , pp. 1432-1439
    • Feldman, D.1    Baum, M.2    Ginsberg, M.3    Hassoun, H.4    Flombaum, C.5    Velasco, S.6
  • 28
    • 84993823450 scopus 로고    scopus 로고
    • Encouraging progression free survival results in subjects with newly diagnosed advanced stage renal cell carcinoma participating in a phase II study testing the safety and activity of a dendritic cell-based immunotherapeutic (AGS-003) in combination with sunitinib
    • Proceedings of the Ninth International Kidney Cancer Symposium, Chicago, IL, USA.
    • Figlin R. Amin A. Dudek A. Logan T. Lance R. Holzbeierlein J. (2010) Encouraging progression free survival results in subjects with newly diagnosed advanced stage renal cell carcinoma participating in a phase II study testing the safety and activity of a dendritic cell-based immunotherapeutic (AGS-003) in combination with sunitinib. Proceedings of the Ninth International Kidney Cancer Symposium, Chicago, IL, USA.
    • (2010)
    • Figlin, R.1    Amin, A.2    Dudek, A.3    Logan, T.4    Lance, R.5    Holzbeierlein, J.6
  • 29
    • 84878834146 scopus 로고    scopus 로고
    • Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: New strategies for overcoming resistance to VEGFR and mTORC1 inhibitors
    • Figlin R. Kaufmann I. Brechbiel J. (2013) Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: New strategies for overcoming resistance to VEGFR and mTORC1 inhibitors. Int J Cancer 13: 788–796.
    • (2013) Int J Cancer , vol.13 , pp. 788-796
    • Figlin, R.1    Kaufmann, I.2    Brechbiel, J.3
  • 30
    • 58149179532 scopus 로고    scopus 로고
    • Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients
    • Finke J. Rini B. Ireland J. Rayman P. Richmond A. Golshayan A. (2008) Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Cancer Res 14: 6674–6682.
    • (2008) Cancer Res , vol.14 , pp. 6674-6682
    • Finke, J.1    Rini, B.2    Ireland, J.3    Rayman, P.4    Richmond, A.5    Golshayan, A.6
  • 31
    • 77958057373 scopus 로고    scopus 로고
    • Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma
    • Finkelstein S. Carey T. Fricke I. Yu D. Goetz D. Gratz M. (2010) Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma. J Immunother 33: 817–827.
    • (2010) J Immunother , vol.33 , pp. 817-827
    • Finkelstein, S.1    Carey, T.2    Fricke, I.3    Yu, D.4    Goetz, D.5    Gratz, M.6
  • 32
    • 85013312416 scopus 로고
    • Tumor angiogenesis: therapeutic implications
    • Folkman J. (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182–1186.
    • (1971) N Engl J Med , vol.285 , pp. 1182-1186
    • Folkman, J.1
  • 33
    • 0029812542 scopus 로고    scopus 로고
    • Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high dose recombinant interleukin-2 therapy
    • Fyfe G. Fisher R. Rosenberg S. Sznol M. Parkinson D. Louie A. (1996) Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high dose recombinant interleukin-2 therapy. J Clin Oncol 14: 2410–2411.
    • (1996) J Clin Oncol , vol.14 , pp. 2410-2411
    • Fyfe, G.1    Fisher, R.2    Rosenberg, S.3    Sznol, M.4    Parkinson, D.5    Louie, A.6
  • 34
    • 0032741283 scopus 로고    scopus 로고
    • Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function
    • Gabrilovich D. Ishida T. Nadaf S. Ohm J. Carbone D. (1999) Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 5: 2963–2970.
    • (1999) Clin Cancer Res , vol.5 , pp. 2963-2970
    • Gabrilovich, D.1    Ishida, T.2    Nadaf, S.3    Ohm, J.4    Carbone, D.5
  • 35
    • 0032400862 scopus 로고    scopus 로고
    • Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo
    • Gabrilovich D. Ishida T. Ovama T. Ran S. Kravtsov V. Nadaf S. (1998) Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92: 4150–4166.
    • (1998) Blood , vol.92 , pp. 4150-4166
    • Gabrilovich, D.1    Ishida, T.2    Ovama, T.3    Ran, S.4    Kravtsov, V.5    Nadaf, S.6
  • 36
    • 84887803855 scopus 로고    scopus 로고
    • Epidemiology and characterization of pediatric and adolescent renal cell carcinoma: a report from the Children–s Oncology Group Study AREN 03B2
    • (Suppl. 2):, abstract 40
    • Geller J. Mullen E. Khanna G. Ehrlich P. Cost N. Naranjo A. (2012) Epidemiology and characterization of pediatric and adolescent renal cell carcinoma: a report from the Children–s Oncology Group Study AREN 03B2. Br J Urol Int 110(Suppl. 2): 18–19, abstract 40.
    • (2012) Br J Urol Int , vol.110 , pp. 18-19
    • Geller, J.1    Mullen, E.2    Khanna, G.3    Ehrlich, P.4    Cost, N.5    Naranjo, A.6
  • 37
    • 58249094490 scopus 로고    scopus 로고
    • Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy
    • Golshayan A. George S. Heng D. Elson P. Wood L. Mekhail T. (2009) Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol 72: 235–241.
    • (2009) J Clin Oncol , vol.72 , pp. 235-241
    • Golshayan, A.1    George, S.2    Heng, D.3    Elson, P.4    Wood, L.5    Mekhail, T.6
  • 38
    • 73349085260 scopus 로고    scopus 로고
    • Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317
    • Gordon M. Hussey M. Nagle R. Lara P. Jr Mack P. Dutcher J. (2009) Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol 27: 5788–5793.
    • (2009) J Clin Oncol , vol.27 , pp. 5788-5793
    • Gordon, M.1    Hussey, M.2    Nagle, R.3    Lara, P.4    Mack, P.5    Dutcher, J.6
  • 39
    • 85059872938 scopus 로고    scopus 로고
    • Use of meta-analysis of clear cell renal cell carcinoma gene expression to define a variant subgroup and identify gender influences on tumor biology
    • (Suppl. 5): abstract 412
    • Haake S. Brannon A. Hacker K. Pruthi R. Wallen E. Nielsen M. (2013) Use of meta-analysis of clear cell renal cell carcinoma gene expression to define a variant subgroup and identify gender influences on tumor biology. J Clin Oncol 30(Suppl. 5): abstract 412.
    • (2013) J Clin Oncol , vol.30
    • Haake, S.1    Brannon, A.2    Hacker, K.3    Pruthi, R.4    Wallen, E.5    Nielsen, M.6
  • 40
    • 84866274288 scopus 로고    scopus 로고
    • Phase II trial of doxorubicin and gemcitabine in metastatic renal cell carcinoma with sarcomatoid features: ECOG 8802
    • Haas N. Lin C. Manola J. Pins M. Liu G. McDermott D. (2009) Phase II trial of doxorubicin and gemcitabine in metastatic renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol 29: 761–767.
    • (2009) Med Oncol , vol.29 , pp. 761-767
    • Haas, N.1    Lin, C.2    Manola, J.3    Pins, M.4    Liu, G.5    McDermott, D.6
  • 41
    • 77952301116 scopus 로고    scopus 로고
    • Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma
    • Hainsworth J. Spigel D. Burris H. III Waterhouse D. Clark B. Whorf R. (2010) Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 28: 1–7.
    • (2010) J Clin Oncol , vol.28 , pp. 1-7
    • Hainsworth, J.1    Spigel, D.2    Burris, H.3    Waterhouse, D.4    Clark, B.5    Whorf, R.6
  • 43
    • 84977120478 scopus 로고    scopus 로고
    • Selecting patients for high-dose interleukin-2 on the basis of tumour histology
    • (Suppl. 9): abstract 808P.
    • Hawkins R. Galvis V. Shablak A. Spencer-Shaw A. Thistlethwaite F. Shanks J. (2012) Selecting patients for high-dose interleukin-2 on the basis of tumour histology. Ann Oncol 23(Suppl. 9): abstract 808P.
    • (2012) Ann Oncol , vol.23
    • Hawkins, R.1    Galvis, V.2    Shablak, A.3    Spencer-Shaw, A.4    Thistlethwaite, F.5    Shanks, J.6
  • 45
  • 46
    • 84879068377 scopus 로고    scopus 로고
    • Subgroup analyses of a phase III trial comparing tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma
    • (Suppl. 6): abstract 354
    • Hutson T. Nosov D. Eisen T. Lipatov O. Tomczak P. Alyasova A. (2013) Subgroup analyses of a phase III trial comparing tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma. J Clin Oncol 31(Suppl. 6): abstract 354.
    • (2013) J Clin Oncol , vol.31
    • Hutson, T.1    Nosov, D.2    Eisen, T.3    Lipatov, O.4    Tomczak, P.5    Alyasova, A.6
  • 47
    • 33846879810 scopus 로고    scopus 로고
    • The von Hippel–Lindau tumor suppressor protein and clear cell renal carcinoma
    • (Res 13
    • Kaelin W. Jr (2007) The von Hippel–Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 13: 680s–684s.
    • (2007) Clin Cancer , pp. 680s-684s
    • Kaelin, W.1
  • 48
    • 84887764201 scopus 로고    scopus 로고
    • Molecular biology of kidney cancer
    • In, Lara, P., Jr, Jonash, E., (eds), Berlin: Springer, pp.
    • Kaelin W. Jr (2012) Molecular biology of kidney cancer. In Lara P. Jr Jonash E. (eds) Kidney Cancer: Principles and Practice. Berlin: Springer, pp. 29–46.
    • (2012) Kidney Cancer: Principles and Practice , pp. 29-46
    • Kaelin, W.1
  • 50
    • 63149147206 scopus 로고    scopus 로고
    • Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry
    • Komai Y. Fujiwara M. Fujii Y. Mukai H. Yonese J. Kawakami S. (2009) Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry. Clin Cancer Res 15: 1170–1176.
    • (2009) Clin Cancer Res , vol.15 , pp. 1170-1176
    • Komai, Y.1    Fujiwara, M.2    Fujii, Y.3    Mukai, H.4    Yonese, J.5    Kawakami, S.6
  • 51
    • 0027240519 scopus 로고
    • Identification of the von Hippel–Lindau disease tumor suppressor gene
    • Latif F. Tory K. Gnarra J. Yao M. Duh F. Orcutt M. (1993) Identification of the von Hippel–Lindau disease tumor suppressor gene. Science 260: 1317–1320.
    • (1993) Science , vol.260 , pp. 1317-1320
    • Latif, F.1    Tory, K.2    Gnarra, J.3    Yao, M.4    Duh, F.5    Orcutt, M.6
  • 52
    • 0029947568 scopus 로고    scopus 로고
    • Enhancement of antitumor immunity by CTLA-4 blockade
    • Leach D. Krummel M. Allison J. (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271: 1734–1736.
    • (1996) Science , vol.271 , pp. 1734-1736
    • Leach, D.1    Krummel, M.2    Allison, J.3
  • 53
    • 84873079111 scopus 로고    scopus 로고
    • The metabolic basis of kidney cancer
    • Linehan W. Ricketts C. (2013) The metabolic basis of kidney cancer. Semin Cancer Biol 23: 46–55.
    • (2013) Semin Cancer Biol , vol.23 , pp. 46-55
    • Linehan, W.1    Ricketts, C.2
  • 54
    • 0037182139 scopus 로고    scopus 로고
    • Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy
    • Luan F. Hojo M. Maluccio M. Yamaji K. Suthanthiran M. (2002) Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 73: 1565–1572.
    • (2002) Transplantation , vol.73 , pp. 1565-1572
    • Luan, F.1    Hojo, M.2    Maluccio, M.3    Yamaji, K.4    Suthanthiran, M.5
  • 55
    • 0032813906 scopus 로고    scopus 로고
    • Hereditary and sporadic papillary renal carcinoma with c-met mutations share a distinct morphological phenotype
    • Lubensky I. Schmidt L. Zhuang Z. Weirich G. Pack S. Zambrano N. (1999) Hereditary and sporadic papillary renal carcinoma with c-met mutations share a distinct morphological phenotype. Am J Pathol 155: 517–526.
    • (1999) Am J Pathol , vol.155 , pp. 517-526
    • Lubensky, I.1    Schmidt, L.2    Zhuang, Z.3    Weirich, G.4    Pack, S.5    Zambrano, N.6
  • 56
    • 77953778637 scopus 로고    scopus 로고
    • Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma: a report from the Juvenile RCC Network
    • Malouf G. Camparo P. Oudard S. Schleiermacher G. Theodore C. Rustine A. (2010) Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma: a report from the Juvenile RCC Network. Ann Oncol 21: 1834–1838.
    • (2010) Ann Oncol , vol.21 , pp. 1834-1838
    • Malouf, G.1    Camparo, P.2    Oudard, S.3    Schleiermacher, G.4    Theodore, C.5    Rustine, A.6
  • 57
    • 78650029087 scopus 로고    scopus 로고
    • TFE3 and TFEB renal cell carcinomas: Clinical features, biological behavior and prognostic factors
    • Malouf G. Camparo P. Molinie V. Dedet G. Oudard S. Schleiermacher G. (2011) TFE3 and TFEB renal cell carcinomas: Clinical features, biological behavior and prognostic factors. J Urol 185: 24–29.
    • (2011) J Urol , vol.185 , pp. 24-29
    • Malouf, G.1    Camparo, P.2    Molinie, V.3    Dedet, G.4    Oudard, S.5    Schleiermacher, G.6
  • 58
    • 84892443803 scopus 로고    scopus 로고
    • Clinical activity and safety of anti-programmed death-1 (PD-1) (BMS-936558/MDX-1106/ONO538) in patients with previously treated metastatic renal cell carcinoma: an updated analysis
    • (Suppl. 6): abstract 351
    • McDermott D. Drake C. Sznol M. Choueiri T. Powderly J. Smith D. (2013a) Clinical activity and safety of anti-programmed death-1 (PD-1) (BMS-936558/MDX-1106/ONO538) in patients with previously treated metastatic renal cell carcinoma: an updated analysis. J Clin Oncol 31(Suppl. 6): abstract 351.
    • (2013) J Clin Oncol , vol.31
    • McDermott, D.1    Drake, C.2    Sznol, M.3    Choueiri, T.4    Powderly, J.5    Smith, D.6
  • 59
    • 78650630648 scopus 로고    scopus 로고
    • The high dose aldesleukin (HD-IL2) “Select” trial in patients with metastatic renal cell carcinoma
    • (15 Suppl.):, abstract 4515
    • McDermott D. Ghebremichael M. Signoretti S. Margolin K. Clark J. Sosman J. (2010) The high dose aldesleukin (HD-IL2) “Select” trial in patients with metastatic renal cell carcinoma. J Clin Oncol 28(15 Suppl.): 345s, abstract 4515.
    • (2010) J Clin Oncol , vol.28 , pp. 345s
    • McDermott, D.1    Ghebremichael, M.2    Signoretti, S.3    Margolin, K.4    Clark, J.5    Sosman, J.6
  • 60
    • 84895782404 scopus 로고    scopus 로고
    • The BeST Trial (ECOG 2804): a randomized phase II study of VEGF, RAF kinase, and MTOR combination targeted therapy with bevacizumab, sorafenib, and temsirolimus in advanced renal cell carcinoma
    • (Suppl. 6): abstract 345
    • McDermott D. Manola J. Pins M. Flaherty K. Atkins M. Dutcher J. (2013b) The BeST Trial (ECOG 2804): a randomized phase II study of VEGF, RAF kinase, and MTOR combination targeted therapy with bevacizumab, sorafenib, and temsirolimus in advanced renal cell carcinoma. J Clin Oncol 31(Suppl. 6): abstract 345.
    • (2013) J Clin Oncol , vol.31
    • McDermott, D.1    Manola, J.2    Pins, M.3    Flaherty, K.4    Atkins, M.5    Dutcher, J.6
  • 61
    • 16644401873 scopus 로고    scopus 로고
    • Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
    • McDermott D. Regan M. Clark J. Flaherty L. Weiss G. Logan T. (2005) Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23: 133–141.
    • (2005) J Clin Oncol , vol.23 , pp. 133-141
    • McDermott, D.1    Regan, M.2    Clark, J.3    Flaherty, L.4    Weiss, G.5    Logan, T.6
  • 62
    • 36749098248 scopus 로고    scopus 로고
    • Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results
    • (18 Suppl.): abstract 5034
    • Merchan J. Liu G. Fitch T. Maples W. Picus J. Erlichman C. (2007) Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results. J Clin Oncol 25(18 Suppl. ): abstract 5034.
    • (2007) J Clin Oncol , vol.25
    • Merchan, J.1    Liu, G.2    Fitch, T.3    Maples, W.4    Picus, J.5    Erlichman, C.6
  • 63
    • 0038514165 scopus 로고    scopus 로고
    • Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial
    • Messing E. Manola J. Wilding G. Propert K. Fleischmann J. Pontes J. (2003) Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 21: 1214–1222.
    • (2003) J Clin Oncol , vol.21 , pp. 1214-1222
    • Messing, E.1    Manola, J.2    Wilding, G.3    Propert, K.4    Fleischmann, J.5    Pontes, J.6
  • 64
    • 80052752436 scopus 로고    scopus 로고
    • Phase II trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor risk metastatic renal cell carcinoma
    • (15 Suppl.):, abstract 340
    • Michaelson M. McDermott D. Atkins M. Cho D. Olivier K. Schwarzberg A. (2010) Phase II trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor risk metastatic renal cell carcinoma. J Clin Oncol 28(15 Suppl.): e15076, abstract 340.
    • (2010) J Clin Oncol , vol.28 , pp. e15076
    • Michaelson, M.1    McDermott, D.2    Atkins, M.3    Cho, D.4    Olivier, K.5    Schwarzberg, A.6
  • 65
    • 84876464041 scopus 로고    scopus 로고
    • Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study
    • Michaelson M. Zhu A. Ryan D. McDermott D. Shapiro G. Tye L. (2013) Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study. Br J Cancer 108: 1393–1401.
    • (2013) Br J Cancer , vol.108 , pp. 1393-1401
    • Michaelson, M.1    Zhu, A.2    Ryan, D.3    McDermott, D.4    Shapiro, G.5    Tye, L.6
  • 66
    • 84880932219 scopus 로고    scopus 로고
    • A phase Ib clinical trial of the multitargeted kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma
    • (Suppl. 6): abstract 358
    • Molina A. Hutson T. Larkin J. Gold A. Andresen C. Wood K. (2013) A phase Ib clinical trial of the multitargeted kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma. J Clin Oncol 31(Suppl. 6): abstract 358.
    • (2013) J Clin Oncol , vol.31
    • Molina, A.1    Hutson, T.2    Larkin, J.3    Gold, A.4    Andresen, C.5    Wood, K.6
  • 67
    • 84878711441 scopus 로고    scopus 로고
    • Overall survival results from a phase III study of tivozanib hydrochloride versus sorafenib in patients with renal cell carcinoma
    • (Suppl. 6): abstract 350
    • Motzer R. Eisen T. Hutson T. Szczylik C. Krygowski M. Strahs L. (2013a) Overall survival results from a phase III study of tivozanib hydrochloride versus sorafenib in patients with renal cell carcinoma. J Clin Oncol 31(Suppl. 6): abstract 350.
    • (2013) J Clin Oncol , vol.31
    • Motzer, R.1    Eisen, T.2    Hutson, T.3    Szczylik, C.4    Krygowski, M.5    Strahs, L.6
  • 68
    • 48649107474 scopus 로고    scopus 로고
    • Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
    • Motzer R. Escudier B. Oudard S. Hutson T. Porta C. Bracarda S. (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449–456.
    • (2008) Lancet , vol.372 , pp. 449-456
    • Motzer, R.1    Escudier, B.2    Oudard, S.3    Hutson, T.4    Porta, C.5    Bracarda, S.6
  • 69
    • 77956227464 scopus 로고    scopus 로고
    • Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors
    • Motzer R. Escudier B. Oudard S. Hutson T. Porta C. Bracarda S. (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116: 4256–4265.
    • (2010) Cancer , vol.116 , pp. 4256-4265
    • Motzer, R.1    Escudier, B.2    Oudard, S.3    Hutson, T.4    Porta, C.5    Bracarda, S.6
  • 70
    • 84876974877 scopus 로고    scopus 로고
    • Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
    • Motzer R. Escudier B. Tomczak P. Hutson T. Michaelson M. Negrier S. (2013b) Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 14: 552–562.
    • (2013) Lancet Oncol , vol.14 , pp. 552-562
    • Motzer, R.1    Escudier, B.2    Tomczak, P.3    Hutson, T.4    Michaelson, M.5    Negrier, S.6
  • 71
    • 34548528069 scopus 로고    scopus 로고
    • Phase I/II trial of temsirolimus, combined with interferon alfa for advanced renal cell carcinoma
    • Motzer R. Hudes G. Curti B. McDermott D. Escudier B. Negrier S. (2007a) Phase I/II trial of temsirolimus, combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol 25: 3958–3964.
    • (2007) J Clin Oncol , vol.25 , pp. 3958-3964
    • Motzer, R.1    Hudes, G.2    Curti, B.3    McDermott, D.4    Escudier, B.5    Negrier, S.6
  • 73
    • 33744954585 scopus 로고    scopus 로고
    • Sunitinib in patients with metastatic renal cell carcinoma
    • Motzer R. Rini B. Bukowski R. Curti B. George D. Hudes G. (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295: 2516–2524.
    • (2006) JAMA , vol.295 , pp. 2516-2524
    • Motzer, R.1    Rini, B.2    Bukowski, R.3    Curti, B.4    George, D.5    Hudes, G.6
  • 74
    • 84874467714 scopus 로고    scopus 로고
    • Cabozantinib for the treatment of advanced medullary thyroid cancer
    • Nagilla M. Brown R. Cohen E. (2012) Cabozantinib for the treatment of advanced medullary thyroid cancer. Adv Ther 29: 925–934.
    • (2012) Adv Ther , vol.29 , pp. 925-934
    • Nagilla, M.1    Brown, R.2    Cohen, E.3
  • 75
    • 4844231761 scopus 로고    scopus 로고
    • Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma
    • Nanus D. Garino A. Milowsky M. Larkin M. Dutcher J. (2004) Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma. Cancer 101: 1545–1551.
    • (2004) Cancer , vol.101 , pp. 1545-1551
    • Nanus, D.1    Garino, A.2    Milowsky, M.3    Larkin, M.4    Dutcher, J.5
  • 76
    • 84869122157 scopus 로고    scopus 로고
    • RAD001 enhances the potency of BEZ235 to inhibit mTOR signaling and tumor growth
    • Nyfeler B. Chen Y. Li X Pinzon-Ortiz M. Wang Z Reddy A. (2012) RAD001 enhances the potency of BEZ235 to inhibit mTOR signaling and tumor growth. PLoS One 7: e48548.
    • (2012) PLoS One , vol.7 , pp. e48548
    • Nyfeler, B.1    Chen, Y.2    Li, X.3    Pinzon-Ortiz, M.4    Wang, Z.5    Reddy, A.6
  • 77
    • 34547794178 scopus 로고    scopus 로고
    • PD-1 and PD-1 ligands: from discovery to clinical application
    • Okazaki T. Honjo T. (2007) PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 19: 813–824.
    • (2007) Int Immunol , vol.19 , pp. 813-824
    • Okazaki, T.1    Honjo, T.2
  • 78
    • 84858766182 scopus 로고    scopus 로고
    • The blockade of immune checkpoints in cancer immunotherapy
    • Pardoll D. (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252–264.
    • (2012) Nat Rev Cancer , vol.12 , pp. 252-264
    • Pardoll, D.1
  • 79
    • 36849031075 scopus 로고    scopus 로고
    • A phase I, pharmacokinetic and pharmacodynamics study of sorafenib, a multi-targeted kinase inhibitor in combination with temsirolimus, an mTOR inhibitor in patients with advanced solid malignancies
    • (18 Suppl.): abstract 3512
    • Patnaik A. Ricart A. Cooper J. Papadopoulos K. Beeram M. Mita C. (2007) A phase I, pharmacokinetic and pharmacodynamics study of sorafenib, a multi-targeted kinase inhibitor in combination with temsirolimus, an mTOR inhibitor in patients with advanced solid malignancies. J Clin Oncol 25(18 Suppl.): abstract 3512.
    • (2007) J Clin Oncol , vol.25
    • Patnaik, A.1    Ricart, A.2    Cooper, J.3    Papadopoulos, K.4    Beeram, M.5    Mita, C.6
  • 81
    • 0035863285 scopus 로고    scopus 로고
    • Interferon adjuvant to radical nephrectomy in Robson Stages II and III renal cell carcinoma: a multicentric randomized study
    • Pizzocaro G. Piva L. Colavita M. Ferri S. Artusi R. Boracchi P. (2001) Interferon adjuvant to radical nephrectomy in Robson Stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 19: 425–431.
    • (2001) J Clin Oncol , vol.19 , pp. 425-431
    • Pizzocaro, G.1    Piva, L.2    Colavita, M.3    Ferri, S.4    Artusi, R.5    Boracchi, P.6
  • 82
    • 2442737061 scopus 로고    scopus 로고
    • Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer
    • Pyrhonen S. Salminen E. Ruutu M. Lehtonen T. Nurmi M. Tammela T. (1999) Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17: 2859–2867.
    • (1999) J Clin Oncol , vol.17 , pp. 2859-2867
    • Pyrhonen, S.1    Salminen, E.2    Ruutu, M.3    Lehtonen, T.4    Nurmi, M.5    Tammela, T.6
  • 83
    • 84887794155 scopus 로고    scopus 로고
    • Randomized phase II study of first line everolimus plus bevacizumab versus interferon alfa 2A plus bevacizumab in patients with metastatic renal cell carcinoma: RECORD-2 final overall survival and safety results
    • (Suppl.): abstract 4576
    • Ravaud A. Barrios C. Alekseev B. Tay M. Agarwala S. Yalcin S. (2013) Randomized phase II study of first line everolimus plus bevacizumab versus interferon alfa 2A plus bevacizumab in patients with metastatic renal cell carcinoma: RECORD-2 final overall survival and safety results. J Clin Oncol 31(Suppl.): abstract 4576.
    • (2013) J Clin Oncol , vol.31
    • Ravaud, A.1    Barrios, C.2    Alekseev, B.3    Tay, M.4    Agarwala, S.5    Yalcin, S.6
  • 84
    • 84874550573 scopus 로고    scopus 로고
    • Randomized phase II study of first line everolimus + bevacizumab versus interferon alfa 2A + bevacizumab in patients with metastatic renal cell carcinoma: RECORD-2
    • (Suppl. 9): abstract 783O.
    • Ravaud A. Barrios C. Anak O. Pelov D. Louveau A. Alekseev B. (2012) Randomized phase II study of first line everolimus + bevacizumab versus interferon alfa 2A + bevacizumab in patients with metastatic renal cell carcinoma: RECORD-2. Ann Oncol 23(Suppl. 9): abstract 783O.
    • (2012) Ann Oncol , vol.23
    • Ravaud, A.1    Barrios, C.2    Anak, O.3    Pelov, D.4    Louveau, A.5    Alekseev, B.6
  • 85
    • 84862882003 scopus 로고    scopus 로고
    • Tumor immunotherapy directed at PD-1
    • Ribas A. (2012) Tumor immunotherapy directed at PD-1. N Engl J Med 366: 2517–2519.
    • (2012) N Engl J Med , vol.366 , pp. 2517-2519
    • Ribas, A.1
  • 86
    • 84874514155 scopus 로고    scopus 로고
    • Randomized phase IIIB trial of temsirolimus and bevacizumab versus interferon and bevacizumab in metastatic renal cell carcinoma: results from INTORACT
    • Suppl. 9): abstract LBA21
    • Rini B. Bellmunt J. Clancy J. Wang K. Niethammer A. Escudier B. (2012) Randomized phase IIIB trial of temsirolimus and bevacizumab versus interferon and bevacizumab in metastatic renal cell carcinoma: results from INTORACT. Ann Oncol 23 (Suppl. 9): abstract LBA21.
    • (2012) Ann Oncol , vol.23
    • Rini, B.1    Bellmunt, J.2    Clancy, J.3    Wang, K.4    Niethammer, A.5    Escudier, B.6
  • 87
    • 82755183572 scopus 로고    scopus 로고
    • Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
    • Rini B. Escudier B. Tomczak P Kaprin A. Szczylik C. Hutson T. (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378: 1931–1939.
    • (2011) Lancet , vol.378 , pp. 1931-1939
    • Rini, B.1    Escudier, B.2    Tomczak, P.3    Kaprin, A.4    Szczylik, C.5    Hutson, T.6
  • 88
    • 77952318310 scopus 로고    scopus 로고
    • Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206
    • Rini B. Halabi S. Rosenberg J. Stadler W. Vaena D. Archer L. (2010) Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28: 2137–2143.
    • (2010) J Clin Oncol , vol.28 , pp. 2137-2143
    • Rini, B.1    Halabi, S.2    Rosenberg, J.3    Stadler, W.4    Vaena, D.5    Archer, L.6
  • 89
    • 56749161699 scopus 로고    scopus 로고
    • Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patient with metastatic renal cell carcinoma. CALGB 90206
    • Rini B. Halabi S. Rosenberg J. Stadler W. Vaena D. Ou S. (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patient with metastatic renal cell carcinoma. CALGB 90206. J Clin Oncol 26: 5422–5428.
    • (2008) J Clin Oncol , vol.26 , pp. 5422-5428
    • Rini, B.1    Halabi, S.2    Rosenberg, J.3    Stadler, W.4    Vaena, D.5    Ou, S.6
  • 90
    • 84870659220 scopus 로고    scopus 로고
    • AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase II study
    • Rini B. Szczylik C. Tannir N. Koralewski P. Deptala A. Dirix L. (2012) AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase II study. Cancer 118: 6152–6161.
    • (2012) Cancer , vol.118 , pp. 6152-6161
    • Rini, B.1    Szczylik, C.2    Tannir, N.3    Koralewski, P.4    Deptala, A.5    Dirix, L.6
  • 91
    • 0037564427 scopus 로고    scopus 로고
    • Negative feedback of T cell activation through inhibitory adapters and costimulatory receptors
    • Saito T. Yamasaki S. (2003) Negative feedback of T cell activation through inhibitory adapters and costimulatory receptors. Immunol Rev 92: 143–160.
    • (2003) Immunol Rev , vol.92 , pp. 143-160
    • Saito, T.1    Yamasaki, S.2
  • 92
    • 0035059417 scopus 로고    scopus 로고
    • Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation
    • Salomon B. Bluestone J. (2001) Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Ann Rev Immunol 19: 225–252.
    • (2001) Ann Rev Immunol , vol.19 , pp. 225-252
    • Salomon, B.1    Bluestone, J.2
  • 93
    • 0034821623 scopus 로고    scopus 로고
    • Birt–Hogg–Dube syndrome, a geodermatosis associated with spontaneous pneumothorax and kidney neoplasia maps to chromosome 17p11.2
    • Schmidt L. Warren M. Nickerson M. Weirich G. Matrosova V. Toro J. (2001) Birt–Hogg–Dube syndrome, a geodermatosis associated with spontaneous pneumothorax and kidney neoplasia maps to chromosome 17p11.2. Am J Hum Genet 69: 876–882.
    • (2001) Am J Hum Genet , vol.69 , pp. 876-882
    • Schmidt, L.1    Warren, M.2    Nickerson, M.3    Weirich, G.4    Matrosova, V.5    Toro, J.6
  • 94
    • 84877923189 scopus 로고    scopus 로고
    • Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib
    • Serova M. deGramont A. Tijeras-Raballand A. Dos Santos C. Riviero M. Slimane K. (2013) Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib. Cancer Chemother Pharmacol 71: 1297–1307.
    • (2013) Cancer Chemother Pharmacol , vol.71 , pp. 1297-1307
    • Serova, M.1    deGramont, A.2    Tijeras-Raballand, A.3    Dos Santos, C.4    Riviero, M.5    Slimane, K.6
  • 95
    • 84887782391 scopus 로고    scopus 로고
    • Pathologic considerations
    • In, Lara, P., Jr, Jonash, E., (eds), Berlin: Springer, pp.
    • Sircar K. Tamboli P. (2012) Pathologic considerations. In Lara P. Jr Jonash E. (eds), Kidney Cancer: Principles and Practice. Berlin: Springer, pp. 17–28.
    • (2012) Kidney Cancer: Principles and Practice , pp. 17-28
    • Sircar, K.1    Tamboli, P.2
  • 96
    • 84873353930 scopus 로고    scopus 로고
    • Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial
    • Smith D. Smith M. Sweeney C. Elfiky A. Logothetis C. Corn P. (2012) Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 30: 11–18.
    • (2012) J Clin Oncol , vol.30 , pp. 11-18
    • Smith, D.1    Smith, M.2    Sweeney, C.3    Elfiky, A.4    Logothetis, C.5    Corn, P.6
  • 97
    • 55349098735 scopus 로고    scopus 로고
    • Updated results of phase I trial of sorafenib and bevacizumab in patient with metastatic renal cell cancer
    • (Suppl.): abstract 5011
    • Sosman J. Flaherty K. Atkins M. McDermott D. Rothenberg M. Vermeulen W. (2008) Updated results of phase I trial of sorafenib and bevacizumab in patient with metastatic renal cell cancer. J Clin Oncol 26(Suppl.): abstract 5011.
    • (2008) J Clin Oncol , vol.26
    • Sosman, J.1    Flaherty, K.2    Atkins, M.3    McDermott, D.4    Rothenberg, M.5    Vermeulen, W.6
  • 98
    • 77149126422 scopus 로고    scopus 로고
    • Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America
    • Stadler W. Figlin R. McDermott D. Dutcher J. Knox J. Miller W. Jr. (2010) Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 116: 1272–1280.
    • (2010) Cancer , vol.116 , pp. 1272-1280
    • Stadler, W.1    Figlin, R.2    McDermott, D.3    Dutcher, J.4    Knox, J.5    Miller, W.6
  • 99
    • 77949890945 scopus 로고    scopus 로고
    • Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial
    • Sternberg C. Davis I. Mardiak J. Szczylik C. Lee E. Wagstaff J. (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28: 1061–1068.
    • (2010) J Clin Oncol , vol.28 , pp. 1061-1068
    • Sternberg, C.1    Davis, I.2    Mardiak, J.3    Szczylik, C.4    Lee, E.5    Wagstaff, J.6
  • 100
    • 33846998680 scopus 로고    scopus 로고
    • Mechanisms of disease: Hereditary leiomyomatosis and renal cell cancer – a distinct form of hereditary kidney cancer
    • Sudarshan S. Pinto P. Neckers L. Linehan W. (2007) Mechanisms of disease: Hereditary leiomyomatosis and renal cell cancer – a distinct form of hereditary kidney cancer. Nat Clin Pract Urol 4: 104–110.
    • (2007) Nat Clin Pract Urol , vol.4 , pp. 104-110
    • Sudarshan, S.1    Pinto, P.2    Neckers, L.3    Linehan, W.4
  • 101
    • 0036897914 scopus 로고    scopus 로고
    • Renal medullary carcinoma: clinical, pathologic, immunohistochemical and genetic analysis with pathogenetic implications
    • Swartz M. Karth J. Schneider D. Rodriguez R. Beckwith J. Perlman E. (2002) Renal medullary carcinoma: clinical, pathologic, immunohistochemical and genetic analysis with pathogenetic implications. Urology 60: 1083–1089.
    • (2002) Urology , vol.60 , pp. 1083-1089
    • Swartz, M.1    Karth, J.2    Schneider, D.3    Rodriguez, R.4    Beckwith, J.5    Perlman, E.6
  • 102
    • 84874869077 scopus 로고    scopus 로고
    • Antagonist antibodies to PD-2 and B7-H1 (PD-L1) in the treatment of advanced human cancer
    • Sznol M. Chen L. (2013) Antagonist antibodies to PD-2 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 19: 1021–1034.
    • (2013) Clin Cancer Res , vol.19 , pp. 1021-1034
    • Sznol, M.1    Chen, L.2
  • 103
    • 33645807880 scopus 로고    scopus 로고
    • Elucidation of the molecular signatures of renal cell carcinoma by gene expression profiling
    • Takahashi M. Teh B. Kanayama H. (2006) Elucidation of the molecular signatures of renal cell carcinoma by gene expression profiling. J Med Invest 53: 9–19.
    • (2006) J Med Invest , vol.53 , pp. 9-19
    • Takahashi, M.1    Teh, B.2    Kanayama, H.3
  • 105
    • 18844386435 scopus 로고    scopus 로고
    • Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy
    • Upton M. Parker R. Youmans A. McDermott D. Atkins M. (2005) Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother 28: 488–495.
    • (2005) J Immunother , vol.28 , pp. 488-495
    • Upton, M.1    Parker, R.2    Youmans, A.3    McDermott, D.4    Atkins, M.5
  • 106
    • 9144249602 scopus 로고    scopus 로고
    • Early-onset renal cell carcinoma as a novel extra-paraganglial component of SDHD-associated heritable paraganglioma
    • Vanharanta S. Buchta M. McWhinney S. Virta S. Peczkowska M. Morrison C. (2004) Early-onset renal cell carcinoma as a novel extra-paraganglial component of SDHD-associated heritable paraganglioma. Am J Hum Genet 74: 153–159.
    • (2004) Am J Hum Genet , vol.74 , pp. 153-159
    • Vanharanta, S.1    Buchta, M.2    McWhinney, S.3    Virta, S.4    Peczkowska, M.5    Morrison, C.6
  • 107
    • 33845307215 scopus 로고    scopus 로고
    • Expanding the morphological and molecular genetic phenotype of kidney cancer
    • Vira M. Linehan W. (2007) Expanding the morphological and molecular genetic phenotype of kidney cancer. J Urol 177: 10–11.
    • (2007) J Urol , vol.177 , pp. 10-11
    • Vira, M.1    Linehan, W.2
  • 108
    • 84869493002 scopus 로고    scopus 로고
    • Tivantinib (ARQ197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial
    • Wagner A. Goldberg J. Dubois S. Choy E. Rosen L. Pappo A. (2012) Tivantinib (ARQ197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer 118: 5894–5902.
    • (2012) Cancer , vol.118 , pp. 5894-5902
    • Wagner, A.1    Goldberg, J.2    Dubois, S.3    Choy, E.4    Rosen, L.5    Pappo, A.6
  • 109
    • 84880936480 scopus 로고    scopus 로고
    • Single-dose cyclophosphamide synergizes with immune response to the renal cell cancer vaccine IMA901
    • Walter S. Weinschenk T. Reinhardt C. Singh-Jasuja H. (2013) Single-dose cyclophosphamide synergizes with immune response to the renal cell cancer vaccine IMA901. Oncoimmunology 2: e22246.
    • (2013) Oncoimmunology , vol.2 , pp. e22246
    • Walter, S.1    Weinschenk, T.2    Reinhardt, C.3    Singh-Jasuja, H.4
  • 110
    • 84864662070 scopus 로고    scopus 로고
    • Multipeptide immune response to cancer vaccine IMA901 after single dose cyclophosphamide associates with longer patient survival
    • Walter S. Weinschenk T. Stenzl A. Zdrojowy R. Pluzanska A Szczylik C. (2012) Multipeptide immune response to cancer vaccine IMA901 after single dose cyclophosphamide associates with longer patient survival. Nat Med 18: 1254–1261.
    • (2012) Nat Med , vol.18 , pp. 1254-1261
    • Walter, S.1    Weinschenk, T.2    Stenzl, A.3    Zdrojowy, R.4    Pluzanska, A.5    Szczylik, C.6
  • 111
    • 4944249117 scopus 로고    scopus 로고
    • Bay 43-9006 exhibits broad spectrum oral antitumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
    • Wilhelm S. Carter C. Tang L. Wilkie D. McNabola A. Rong H. (2004) Bay 43-9006 exhibits broad spectrum oral antitumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099–7109.
    • (2004) Cancer Res , vol.64 , pp. 7099-7109
    • Wilhelm, S.1    Carter, C.2    Tang, L.3    Wilkie, D.4    McNabola, A.5    Rong, H.6
  • 113
    • 0042343801 scopus 로고    scopus 로고
    • A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
    • Yang J. Haworth L. Sherry R. Hwu P. Schwartzentruber D. Topalian S. (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427–434.
    • (2003) N Engl J Med , vol.349 , pp. 427-434
    • Yang, J.1    Haworth, L.2    Sherry, R.3    Hwu, P.4    Schwartzentruber, D.5    Topalian, S.6
  • 114
    • 37349072460 scopus 로고    scopus 로고
    • Ipilimumab (anti-CTLA-4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis
    • Yang J. Hughes M. Kammula U. Royal R. Sherry R. Topalian S. (2007) Ipilimumab (anti-CTLA-4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 30: 825–830.
    • (2007) J Immunother , vol.30 , pp. 825-830
    • Yang, J.1    Hughes, M.2    Kammula, U.3    Royal, R.4    Sherry, R.5    Topalian, S.6
  • 115
    • 10744231407 scopus 로고    scopus 로고
    • Gene expression profiling of renal medullary carcinoma: potential clinical relevance
    • Yang X. Sugimura J. Tretiakova M. Furge K. Zagaja G. Sokoloff M. (2004) Gene expression profiling of renal medullary carcinoma: potential clinical relevance. Cancer 100: 976–985.
    • (2004) Cancer , vol.100 , pp. 976-985
    • Yang, X.1    Sugimura, J.2    Tretiakova, M.3    Furge, K.4    Zagaja, G.5    Sokoloff, M.6
  • 116
    • 77953816103 scopus 로고    scopus 로고
    • Molecular pathology of renal oncocytoma: A review
    • Yusenko M. (2010) Molecular pathology of renal oncocytoma: A review. Int J Urol 17: 602–612.
    • (2010) Int J Urol , vol.17 , pp. 602-612
    • Yusenko, M.1

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.